Children with sickle cell disease (SCD) were shown to have annual medical costs of $9369 (Medicaid) and $13,469 (private insurance), which is significantly higher than that for children without SCD, according to a study led by Djesika D. Amendah, PhD, an economist at the CDC.1 SCD in children... More »
Separate patterns of comorbidity are identified in patients who have fibromyalgia syndrome (FMS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and noninflammatory rheumatic disorders (NIRD). The patterns include the type of comorbid variables reported and their associations with... More »
Parkinson disease (PD) is associated with a number of nonmotor symptoms, including depression, drug-induced psychosis and impulse control disorders, cognitive impairment, anxiety, and sleep disturbances. More »
Parkinson disease (PD) is the second most common neurodegenerative illness in the United States, affecting more than 1 million persons. Disease onset is usually after age 50. In persons older than 70 years, the prevalence is 1.5% to 2.5%.1 While the primary pathology involves degeneration of... More »
There are significant associations between the increased numbers of telangiectases in patients with scleroderma and the presence of pulmonary arterial hypertension (PAH). Cutaneous telangiectases may be a manifestation of the vasculopathy of scleroderma that could serve as a clinical biomarker for... More »
Women with systemic lupus erythematosus (SLE) are at increased risk for coronary artery disease (CAD) and mortality. The dominant risk factors are SLE itself, age, and high total triglyceride levels rather than the traditional Framingham risk factors. More »
The objective of this study was to estimate the annual cost burden of Parkinson disease (PD) in the United States. Resource use and cost profiles were developed using all-payer statewide hospital discharge data from 6 states; emergency department visit, long-term–care, and national survey data; fee... More »
